National Institutes of Health–Sponsored Clinical Islet Transplantation Consortium Phase 3 Trial: Manufacture of a Complex Cellular Product at Eight Processing Facilities

نویسندگان

  • Camillo Ricordi
  • Julia S. Goldstein
  • A.N. Balamurugan
  • Gregory L. Szot
  • Tatsuya Kin
  • Chengyang Liu
  • Christine W. Czarniecki
  • Barbara Barbaro
  • Nancy D. Bridges
  • Jose Cano
  • William R. Clarke
  • Thomas L. Eggerman
  • Lawrence G. Hunsicker
  • Dixon B. Kaufman
  • Aisha Khan
  • David-Erick Lafontant
  • Elina Linetsky
  • Xunrong Luo
  • James F. Markmann
  • Ali Naji
  • Olle Korsgren
  • Jose Oberholzer
  • Nicole A. Turgeon
  • Daniel Brandhorst
  • Xiaojuan Chen
  • Andrew S. Friberg
  • Ji Lei
  • Ling-jia Wang
  • Joshua J. Wilhelm
  • Jamie Willits
  • Xiaomin Zhang
  • Bernhard J. Hering
  • Andrew M. Posselt
  • Peter G. Stock
  • A.M. James Shapiro
چکیده

Eight manufacturing facilities participating in the National Institutes of Health-sponsored Clinical Islet Transplantation (CIT) Consortium jointly developed and implemented a harmonized process for the manufacture of allogeneic purified human pancreatic islet (PHPI) product evaluated in a phase 3 trial in subjects with type 1 diabetes. Manufacturing was controlled by a common master production batch record, standard operating procedures that included acceptance criteria for deceased donor organ pancreata and critical raw materials, PHPI product specifications, certificate of analysis, and test methods. The process was compliant with Current Good Manufacturing Practices and Current Good Tissue Practices. This report describes the manufacturing process for 75 PHPI clinical lots and summarizes the results, including lot release. The results demonstrate the feasibility of implementing a harmonized process at multiple facilities for the manufacture of a complex cellular product. The quality systems and regulatory and operational strategies developed by the CIT Consortium yielded product lots that met the prespecified characteristics of safety, purity, potency, and identity and were successfully transplanted into 48 subjects. No adverse events attributable to the product and no cases of primary nonfunction were observed.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Erratum. National Institutes of Health–Sponsored Clinical Islet Transplantation Consortium Phase 3 Trial: Manufacture of a Complex Cellular Product at Eight Processing Facilities. Diabetes 2016;65:3418–3428

Camillo Ricordi, Julia S. Goldstein, A.N. Balamurugan, Gregory L. Szot, Tatsuya Kin, Chengyang Liu, Christine W. Czarniecki, Barbara Barbaro, Nancy D. Bridges, Jose Cano, William R. Clarke, Thomas L. Eggerman, Lawrence G. Hunsicker, Dixon B. Kaufman, Aisha Khan, David-Erick Lafontant, Elina Linetsky, Xunrong Luo, James F. Markmann, Ali Naji, Olle Korsgren, Jose Oberholzer, Nicole A. Turgeon, Da...

متن کامل

Co-Transplantation of VEGF-Expressing Human Embryonic Stem Cell Derived Mesenchymal Stem Cells to Enhance Islet Revascularization in Diabetic Nude Mice

Background: Pancreatic islet transplantation has emerged as a promising treatment for type I diabetes. However, its efficacy is severely hampered due to poor islet engraftment and revascularization, which have been resulted to partially loss of transplanted islets. It has been shown that local delivery of vascular endothelial growth factor (VEGF) could accelerate transplanted islet revasculari...

متن کامل

Advances in islet cell biology: from stem cell differentiation to clinical transplantation: conference report.

The 3rd Annual Rachmiel Levine Symposium entitled "Advances in Islet Cell Biology-From Stem Cell Differentiation to Clinical Transplantation" was organized by the Department of Diabetes, Endocrinology and Metabolism at the City of Hope National Medical Center, with the support of the Southern California Islet Cell Resources Center, American Diabetes Association-David Shapiro Research Fund, Ross...

متن کامل

Getting It Right: Being Smarter about Clinical Trials

June 2006 | Volume 3 | Issue 6 | e144 Concerns about adverse events, including deaths, in recent large clinical trials, both publicly and privately sponsored, prompted Elias A. Zerhouni, Director, National Institutes of Health (NIH) to convene a meeting at the NIH on January 11–12, 2005, to discuss “Moving from Observational Studies to Clinical Trials: Why Do We Sometimes Get It Wrong?” (a deta...

متن کامل

A multicenter feasibility study of chronic graft-versus-host disease according to the National Institute of Health criteria: efforts to establish a Brazil-Seattle consortium as a platform for future collaboration in clinical trials

BACKGROUND: New criteria for the diagnosis and classification of chronic graft-versus-host disease were developed in 2005 for the purpose of clinical trials with a consensus sponsored by the National Institute of Health. OBJECTIVES: The aim of this study is to present the results of a multicenter pilot study performed by the Brazil-Seattle chronic graft-versus-host disease consortium to determ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 65  شماره 

صفحات  -

تاریخ انتشار 2016